71
Participants
Start Date
March 31, 2013
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
Pegylated-Interferon-lambda
Ribavirin
Daclatasvir
Local Institution, Camperdown
Local Institution, Melbourne
Local Institution, Herston
Local Institution, Herston
Local Institution, Adelaide
Local Institution, Torino
Hospital Of The University Of Pennsylvania, Philadelphia
Local Institution, Milan
Local Institution, Madrid
Local Institution, Montpellier
Local Institution, Grenoble
Local Institution, Seville
Local Institution, Florence
Local Institution, Bucharest
Local Institution, Vandœuvre-lès-Nancy
Rush University Medical Center, Chicago
Local Institution, Lyon
Local Institution, Paris
Local Institution, Paris
Clinical Research Centers Of America, Murray
Stanford Boswell Clinic, Palo Alto
Local Institution, Moscow
Local Institution, Saint Petersburg
Local Institution, Iași
Local Institution, Iași
Local Institution, Constanța
Local Institution, Roma
Local Institution, Amsterdam
Local Institution, Nijmegen
Local Institution, Rotterdam
Local Institution, Utrecht
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY